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Abstract: Human platelet products have emerged as an alternative treatment for a range of 
ocular surface diseases such as dry eye and corneal ulceration. With significant therapeutic 
potential and increasing popularity, this study aimed to conduct a systematic review to detail 
the various production methods involved in generating platelet-derived products, compare 
and analyze clinical findings across available studies, and disseminate the relative advan-
tages, limitations, and challenges of using platelet products to treat ocular surface disease. 
Thirty-eight clinical studies were identified, excluding studies conducted in animals and non- 
English language. Studies reported clinical outcomes, which included ocular surface disease 
index, best-corrected visual acuity, and corneal fluorescein staining. Most clinical studies 
reported improved patient signs and symptoms with an increasing variety of human platelet 
products including platelet rich plasma eye drops, human platelet lysate and platelet gels. 
However, due to variations in production methods, and study designs as well as confusing 
terminology, it was suggested that characterization of platelet products is needed for proper 
evaluation across studies. 
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Introduction
Human platelets were first observed as early as 1865, but were considered as 
deformed or altered leukocytes or described as a fibrin clot.1 It was not until 
1881 that they were identified as an independent composition of blood and their 
role in wound healing and coagulation determined.1 Research has identified an 
increasing complexity of human platelet anatomy and identified roles beyond 
coagulation. Accordingly, the use of human platelets has extended from incorporat-
ing treatment of hematological disease to a role in skin regeneration,2 muscle 
healing,3 joint regeneration,4 stem cell culturing,5,6 and ophthalmic surface 
treatment,7,8 thereby making it a key element in regenerative medicine.
Platelets store a wide range of biologically active agents inside vesicles known 
as granules. Some of these active agents include growth factors such as platelet- 
derived growth factor (PDGF), epidermal growth factor (EGF), fibroblast growth 
factor (FGF), transforming growth factor (TGF), nerve growth factor (NGF), and 
insulin-like growth factor (IGF); and cytokines and chemokines.9 Upon platelet 
activation, either via chemical activation or by physical rupturing of platelet cells, 
these bioactive molecules are released and have been reported to play an important 
role in regulating wound healing and tissue regeneration. The interaction between 
these molecules and their respective receptors in the tissue microenvironment can 
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lead to overall reduced inflammation and the activation of 
growth related signaling pathways that facilitate wound 
healing.10 The primary form of the platelet product cur-
rently used in clinic is called platelet rich plasma (PRP). 
PRP is generated initially by isolating and then concen-
trating platelets into small amounts of plasma. Several 
additional methods have been developed to generate PRP 
and through research, further platelet-derived products 
have been developed including leukocyte rich PRP (L- 
PRP, LR-PRP or W-PRP), platelet concentrated plasma 
(PCP), non-coagulating platelet-derived factor concentrate 
(PFC), platelet gel (PG), platelet lysate (PL), platelet rich 
fibrin (PRF), and platelet-rich growth factors (PRGF).11,12 
It is highly likely that through fresh research, the list of 
products and applications will continue to expand.
Although a consistent, internationally recognized clas-
sification system for platelet products remains unavailable 
to researchers, there is general agreement in describing 
PRP derived from disparate methods and subsequent deri-
vative products. Understanding these differences, however, 
is central to the broader investigation of clinical efficacy 
and the interchangeability of products for the treatment of 
ophthalmic disease.
PRP is the platform for all platelet-derived products 
and can be prepared in numerous ways. Briefly, the pre-
paration methods for PRP used for ophthalmic products 
can be classified into single or two-step centrifugations 
with the single centrifugation process most used in 
ophthalmic clinics (Table 1). Terminology of PRP pro-
ducts vary based largely on group preferences and include 
eye-PRP (E-PRP) which was developed directly for 
ophthalmic purposes and PRGF, a derivative from dental 
surgery. Other known ophthalmic terminology includes 
platelet-derived eye drops, PRGD [plasma rich in plate-
let-derived growth factors (PDGF) eye drops] and com-
mercially made PRP. The two-step centrifugation 
preparation method is routinely used by blood banks for 
platelet transfusion and represents the classic method for 
generating PRP. The two-step centrifuge method generates 
PRP with platelet counts at 109 level compared to the one 
step centrifuging method of 108 (Table 1). To our knowl-
edge, no clinical comparison of PRP products has been 
undertaken within ophthalmology.
Human platelet lysate (PL) is essentially PRP activated 
by a freeze/thaw process.13–17 Typically, the platelet con-
centrate is frozen at −80°C however −30°C remains sui-
table for further use and may reflect an available option 
within the hospital environment. The concentrate is then 
thawed at 37°C to break up the platelets.13,14 The process 
targets growth factor release and may not necessarily lead 
to gel formation which is essential to clinical use.17 The 
number of freeze/thaw cycles used in different studies 
range from one to five.15,16 A comparison of the optimal 
number of freeze/thaw cycles and the exact conditions of 
each cycle is yet to be published.
Platelet activation may also form a fibrin matrix, often 
referred to as PRF and PG. The development of PRF was 
reviewed18 and associated terminology identified two 
major types of platelet-derived fibrin matrix: those self- 
clotted and those formed through the addition of exogen-
ous activator/coagulation factors. Based on their recom-
mendations, the term PRF should be used only when 
referring to the self-clotted fibrin matrix.18,19
Furthermore, fibrin matrix formed by addition of coa-
gulation factors was designated the name platelet-rich 
fibrin matrix (PRFM).18 Other publications have used 
PG,20 E-PRP clot,8 or PRGF gel.21 Unfortunately, no 
single terminology has been accepted to encompass this 
formulation for easy reference and subsequently we use 
PG to refer to fibrin matrix formed when liquid PRP 
products are exposed to thrombin or calcium chloride (in 
order to stimulate fibrin formation and platelet 
degranulation).22 Little is known of the biological, physi-
cal, and clinical differences between self-assembled fibrin 
matrix and PG.
As expected, the rapid development in platelet research 
has not been without challenges. Variation in method pre-
paration, confusing terminology and unclear classification 
and reporting requirements for existing products have 
made it difficult for both scientists and clinicians to eval-
uate function and efficacy across published papers. This 
review will focus on the relative advantages and disadvan-
tages of the clinical application of various platelet products 
in treating ocular surface diseases. In doing so, we hope to 
provide guidance on the criteria required for the develop-
ment and accurate reporting of platelet products in clinical 
ophthalmology.
Materials and Methods
Data Sources and Searches
The study was performed in accordance with Preferred 
Reporting Items for Systematic Reviews and Meta- 
Analyses.23 The search was performed to find relevant 
literature examining the therapeutic use of platelet pro-
ducts in treating ocular surface diseases. Relevant studies 
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were retrieved from PubMed using the following key-
words: platelet rich plasma OR plasma rich in growth 
factors OR platelet lysate OR platelet glue AND ocular. 
Due to low strength of evidence coupled with the signifi-
cant variations of PRP used, a meta-analysis was consid-
ered inappropriate and an independent evaluation of 
studies undertaken. This review aims to identify efficacy 
and safety across available products and to detail the 
variety in preparation methods and protocols between 
studies.
Study Selection
The search generated 117 papers. Results were screened 
using inclusive criteria of original clinical study papers, 
use of human subjects, eye disease, English language and 
excluding duplicates which led to 35 clinical papers. 
Review and individual clinical papers were further 
screened for clinical studies not previously identified 
which led to an additional 3 clinical papers. In total, we 
identified 38 clinical papers (Table 2).
Measurements
All the clinical studies were graded into clinical evidence 
levels according to Evidence-based Nursing Care 
Guidelines24 as follows. Level I: systematic review or 
meta-analysis of randomized controlled trials (RCTs) or 
three or more RCTs of good quality with similar results. 
Level II: at least one well designed RCT. Level III: con-
trolled trials with or without randomization. Level IV: 
well-designed case-control or cohort studies. Level V: 
systematic reviews of descriptive and qualitative studies. 
Level VI: single descriptive or qualitative study. Level 
VII: expert opinion.24 Different subjective and objective 
utilities were used to quantify and evaluate the effect of 
platelet products on the treatment of ocular surface dis-
orders. Typically, studies reported the following interna-
tionally recognised scores: ocular surface disease index 
(OSDI) for symptom analysis; best-corrected visual acuity; 
visual analogy scale; Schirmer test; tear breakup time 
(TBUT); and corneal fluorescein staining.
Results
Analysis
The platelet products used in current clinical studies have 
shown composition differences in platelet numbers, 
growth factors, activation stage (freeze-thaw cycle, cal-
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injections, or surgical dressings. Twenty-three clinical stu-
dies used PRP in the form of eye drops, among which 
twenty reported using PRP eye drops and three used PL. 
Notably eighteen of the twenty studies either transported 
PRP eye drops frozen or instructed patients to store unused 
portions frozen. As mentioned previously, the thawing 
process inevitably activates platelets turning PRP into 
PL. The two remaining studies instructed patients to keep 
PRP eye drops in the fridge and therefore remain the only 
studies that can be truly referred to as using PRP.25,26 The 
lack of awareness of the freeze/thaw activation disavows 
any reasonable comparison between the efficacy of PRP 
and PL in treating ocular conditions. Additionally, PRP 
eye drops were prepared without dilution, whereas PL eye 
drops were diluted with saline by either 30% or 50% (v/v). 
The variable dilution further prevents a direct comparison 
across studies. We believe the difference between PRP and 
PL should be addressed in all future clinical studies to 
provide a consistent reporting system and to evaluate if the 
differences in growth factor levels are clinically relevant.
Primary and Secondary Dry Eye Diseases
Among all studies treating dry eye diseases (DED), Avila 
et al27 was designated at clinical evidence level II, and 
Garcia-Conca et al28 at clinical level III. Both studies 
included a comparison group and used PRP eye drops. 
Avila et al used a prospective, randomized, consecutive 
intervention design. All patients had Sjogren’s-related dry 
eye and were divided into the treatment group using auto-
logous PRP eye drops made by the clinic (n = 15) or the 
comparison group treated with hyaluronic acid drops (n = 
15). Generated PRP was injected into the lacrimal gland 
monthly (up to 3 months). All patients in the treatment 
group showed improvement in symptoms and significantly 
improved TBUT scores, and greater reduction in corneal 
fluorescein staining compared to control cohort with no 
adverse effects observed. The limited sample size pre-
cluded broader application of success in a larger popula-
tion, however. Garcia-Conca et al conducted a prospective, 
randomized, blinded intervention study for patients with 
hypo-secretory dry eye. Forty-four were treated with PRP 
eye drops generated by RegenKit and 39 treated with 
artificial tears for 30 days. Both treatments improved 
OSDI scores however the PRP group showed more sig-
nificant and immediate improvement in symptoms across 
the treatment period. The authors suggested this may be 
due to the biological stability of growth factors and plate-
lets being affected over time.
Among the rest of studies that ranked at clinical 
evidence IV or lower, Alio et al, 2017, conducted a 
non-randomized, non-comparison monotherapy review 
using E-PRP in 368 patients with moderate to severe 
dry eye, representing the largest available cohort.29 The 
patients were instructed to use E-PRP eye drops 6 times 
a day for 6 weeks. Over 80% of patients showed 
improvement in symptoms, and 28.8% improved at 
least 1 line of best-corrected visual acuity. 
Concurrently, over 75% of patients showed a reduction 
in clinical signs from baseline. Similar findings have 
been reported by other studies using both PRP eye 
drops and PL eye drops (Table 2).
Significant improvements in patient symptoms and 
clinical signs including both corneal epithelial cell and 
nerve plexus density were found in Sjogren syndrome 
patients treated with PL eye drops compared to patients 
treated with preservative free artificial tears.30 Pezzotta 
et al used PL eye drops to treat graft versus host disease 
(GVHD) patients (n=31) for a duration of 6 months and 
showed that the patients responded to the treatment, with a 
significant improvement in dry eye symptoms.31 Zallio 
et al similarly used autologous PL eye drops over an 
extended period (12 months) in patients suffering from 
chronic GVHD and found that 86% experienced remission 
of objective corneal signs and 73% had improved subjec-
tive national standardized health scores including 8% of 
patients who described complete resolution of dry eye 
symptoms.32
Laser in situ keratomileusis (LASIK) surgery is the 
most commonly performed refractive surgical procedure.33 
Post-LASIK ocular surface syndrome (OSS) is used to 
describe a spectrum of DED following surgery. Alio et al 
in 2007 showed that post-LASIK dry eye symptoms 
improved in 85% of patients treated with E-PRP. Three 
eyes presented with severe punctate keratitis (1.9%) fol-
lowing surgery, all of which healed completely.34 
Conjunctival hyperemia improved in 93.3% of the patients 
with previous signs of ocular surface inflammation. More 
recently, a retrospective, comparative study of 77 eyes in 
42 patients suffering from post-LASIK OSS, showed that 
1–4 cycles of treatment with PRGF (1 cycle = 6 weeks, 4 
drops/day) significantly improved the symptoms compared 
to standard treatments inclusive of artificial tears and 
corticosteroids.34
Only four studies have reported adverse effects. 
Sanchez-Avila et al used autologous immuno-safe PRGF 
(PRGF prepared with an additional heating step at 56°C 
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for 60 min) to treat 26 patients with Sjogren syndrome.35 
Two patients developed eye irritation directly related to the 
use of PRGF. Pezzotta et al used autologous platelet lysate 
to treat 26 patients with GVHD and found 2 patients had 
relapse of symptoms.31 Alio et al in 2007 used E-PRP to 
treat 13 dry eye patients due to corneal laser refractive 
surgery with one patient developing intolerance to PRP 
after 4 weeks.34 No further explanation has been given by 
these groups. Valentini et al used platelet-derived eye 
drops (autologous PRP prepared in-house) on 6 GVHD 
patients with 2 patients experiencing burning and ocular 
discomfort.36
Corneal Ulcers
Topical platelet-derived products and platelet glue have 
been used to treat corneal ulcers and epithelial defects. 
The main cause of persistent epithelial defects (PED) is 
direct ocular injury, however the condition may be exacer-
bated through various pathologies including neurotrophic 
keratopathy, GVHD or herpes simplex infection.37–39 
Conventional treatments such as artificial tears, therapeutic 
contact lenses, anti-inflammatory drops and oral antibio-
tics will provide symptomatic relief, however, often do 
little to provide long-term resolution of the condition.
Autologous PRP eye drops have been reported in 
numerous studies as an effective treatment for corneal 
ulcers. Alio et al in 2007 used it on 26 patients with 
PED caused by either neurotrophic, herpetic or immuno-
logic factors not responsive to conventional treatments. 
The authors found that 50% of corneal ulcers resolved 
with an additional 42% showing significant clinical 
improvement.40 Only 2 eyes showed no clinically signifi-
cant change. No explanation was provided to identify a 
lack of response. Furthermore, inflammation and pain 
were reduced in all patients.40 Alio et al in 2018 also 
used autologous PRP eye drops to treat 44 eyes of 28 
patients with dormant ulcerations caused by surgery 
including keratoplasty, refractive surgery, cross-linking 
and chronic post-surgical corneal edema.41 Here, almost 
two-thirds of patients (59.1%) experienced a reduction or 
complete closure of the ulcer and subsequent improvement 
in visual acuity by at least one line of best-corrected visual 
acuity (65.1%). The majority (90.9%) of patients reported 
an improvement of symptoms.
Wrobel-Dudzinska et al used autologous PRP eye 
drops on 25 patients with neurotrophic corneal ulcers 
caused by herpes infection or cranial nerve palsy (V or 
VII), and no prior response to conventional treatment.42 
The authors showed that at 3 months post-treatment, 80% 
of patients were healed, and of the remaining patients, 
16% experienced a reduction in size, depth, and inflam-
matory status of the ulceration. The progression of corneal 
thinning was halted in all patients.42 Both autologous and 
allogenic PRP eye drops were examined by Ronci et al. 
Autologous PRP was used in 9 patients and allogenic PRP 
was used to treat only one patient with GVHD. Although 
all eyes reported improvement and similar healing time the 
small sample size prevents a direct comparison on the 
effectiveness between autologous and allogenic PRPart.43
The use of PRGF eye drops has been examined in PED 
and ulceration caused by various conditions. Kim et al 
treated a total of 28 eyes experiencing PED following an 
episode of infectious keratitis, and found that the healing 
rate of the corneal epithelium was significantly higher in 
the group treated with PRGF compared to autologous 
serum group.44 In a separate study, PRGF activated by 
calcium, was used to treat 18 patients for PED, with 
85% of participants showing resolution within 11 weeks.45
Two studies evaluated the efficacy of PRGF in the 
treatment of corneal burns. One study used PRGF to 
treat 35 patients with moderate and severe ocular alkali 
burns, finding that corneal and conjunctival healing time 
was reduced with PRGF compared to conventional topical 
treatment and autohemotherapy treatment.46 Panda et al 
compared PRGF to artificial tears on PED caused by grade 
III to V chemical injuries (n = 10).47 Day 7 showed a 
significant reduction in epithelial defect area in the eyes 
treated with PRGF, despite no significant difference in 
overall healing time between the two groups. Eyes treated 
with PRGF also showed improved corneal transparency 
and visual acuity in comparison to standard treatment 
alone.
The clinical use of PG has mainly been examined in 
perforated corneal ulcers. Alio et al, 2013, generated PG 
by activating the autologous PRP with calcium, terming 
the autologous PRP used in their studies E-PRP and PG as 
solid E-PRP or E-PRP clot.48 They used PG in conjunction 
with other membranes including amniotic membrane, tuto-
patch or autologous fibrin membrane to treat various per-
forated corneal conditions.48 In all treatments, PG was 
placed directly in contact with the perforated site with 
other membranes acting as an anchor placed on top of 
PG and sutured into the conjunctiva.48
In conjunction with amniotic membrane, Alio et al, 2007, 
applied PG to 14 eyes with perforations or impending per-
forations. All eyes showed reduced inflammation and pain, 
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and 10 of 14 eyes healed completely. There was no direct 
comparison to amniotic membrane alone.40 In conjunction 
with tutopatch, six cases of corneal perforation resulting from 
severe corneal ulcerations were successfully sealed with no 
relapses or perforations detected in 5 of 6 cases after 3 
months. The only case which relapsed had additional severe 
limbal stem cell deficiency.49 When PG was used in combi-
nation with autologous fibrin membrane with central perfo-
rated ulcers (n =11), all perforations were sealed, and 
epithelial closures were observed in all patients. Stromal 
thinning was observed in less than half of all patients (5 of 
11).48,49 No infection, inflammation or other clinical symp-
toms (pain, discomfort and other complications) were 
observed in all patients, and no relapses were detected after 
3 months follow-up. The fibrin membrane gradually disap-
peared after the initial 3–5 days, allowing 7 of 11 patients to 
undergo corneal grafting following the initial treatment.
Other Indications
We identified 5 other conditions using platelet products, 
and one negative case report. The 5 conditions include: 
injecting E-PRP into anterior chamber to treat keratoconus 
hydrops (one case),50 intracameral E-PRP injection to treat 
ocular hypotension post glaucoma surgery (one case),51 
using PRP from blood bank to mix with other materials 
to form a moldable paste to reconstruct orbital floor frac-
ture (10 cases),52 injecting autologous PRP to treat retinitis 
pigmentosa (37 patients),53 and using PRGF fibrin mem-
brane to treat medically uncontrolled primary open angel 
glaucoma (n=10).54 All these studies reported positive 
outcomes with significant improvement in clinical signs 
and symptoms.
One case reported irreversible blindness (severe ische-
mia) caused by injecting autologous PRP into peri-ocular 
area in a skin rejuvenation treatment. This treatment was 
performed by an unlicensed practitioner and details of PRP 
preparation not recorded.55
Discussion
In the present study, we conducted a comprehensive sys-
tematic review based on published studies in the last 10 
years pertaining to the use of platelet products for the 
treatment of ocular surface diseases.
In the treatment of DED, all clinical studies reported a 
positive outcome in at least two-thirds of patients using 
various platelet products to treat dry eye disease including 
both primary or secondary (Sjogren, GVHD or refractive 
surgery) (Table 1). This suggests that all products, 
although variable in growth factor content, were able to 
assist in healing. In cases where patients were experien-
cing ocular discomfort,36 the authors measured various 
cytokine concentrations in the PRP and patient’s plasma 
and found that they were similar. Furthermore, these 
patients had a higher level of chemokine (C-X-C motif) 
ligand 10 (CXCL10), a crucial protein involved in devel-
oping cutaneous GVHD and in skin-related inflammation 
which may be detrimental to the ocular surface. It is 
possible the cytokines may have been generated during 
the PRP preparation process suggesting the potential 
downside of using a patient’s own plasma when patient 
health may be intrinsically compromised.36 A further 
study showed that although PRP drops may be beneficial 
in promoting epithelial status after LASIK, it had no 
positive effect on the recovery of corneal sensitivity. This 
may be due to the limited bioavailability of growth factors 
in corneal stroma when the substance is topically 
administered.56 It is also possible that the variability 
found across studies may have simply reflected the initial 
clinical presentation which ranged from mild dry eye as 
found in post-refractive surgery eyes to severe ocular sur-
face irritation as commonly found in patients with GVHD.
For the treatment of corneal ulceration, most studies 
indicate a clinical improvement using platelet products. 
However, one study suggested that PRP may provide 
limited effect albeit in a minimal sample.25 In their 
study, autologous PRP was used to treat three cases: cor-
neal ulceration associated with diabetic neurotrophy, cor-
neal ulceration with a diffuse corneal epithelial defect with 
severe infiltration and corneal infection with herpetic ker-
atitis combined with limbal deficiency. Autologous PRP 
was used for all cases. PRP treatment was found to be 
effective in healing the epithelial defect, however corneal 
scarring and stromal infiltration were minimally respon-
sive to PRP treatment. This suggests that the regenerative 
ability of platelet preparations may also be dependent on 
both the concurrent medical condition and the depth of 
ulceration. Further investigations in a similar, larger sam-
ple are required. In a separate study, it was also found that 
allogenic PRP had significantly higher platelet counts and 
at least two-fold higher amount of growth factors includ-
ing PDGF AA, PDGF BB, vascular endothelial growth 
factor (VEGF) and EGF compared to autologous PRP.43 
Despite the small sample size, the similar healing times 
between the two types of PRP may give insight into the 
minimum requirement of growth factors necessary for 
corneal healing. The same study also indicated that one 
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freeze/thaw cycle significantly increased the level of 
growth factors in both types of PRPs,43 inferring that 
platelet activation via freeze/thaw should become a neces-
sary production step.
For the treatment of perforated corneas, combining PG 
with different membranes can be a safe and effective 
remedy. It is believed that the combination treatment pro-
vides a better outcome due to the increased amount of 
growth factors available. Future investigation of PG of 
variable composition may provide an option without the 
requirement of an additional membrane. This may mini-
mise the risk of intraoperative complications, improving 
overall healing time and comfort for the patient.
In most studies reported, various platelet related pro-
ducts have shown improvement in cases that were not 
responsive to conventional methods. The variety of study 
designs and products available however, suggest more 
appropriate methodology and consistency of products is 
essential to understand the mechanism of action. Equally 
important is perhaps the characterization of the generated 
platelet products with few studies reporting growth factor 
levels, platelet counts, presence of leukocytes, and cyto-
kine levels. This information is crucial for comparison 
across the studies, and to investigate the factors that pro-
mote treatment or cause the adverse effect. We cannot 
conclude if the different types of platelet products have a 
unique therapeutic effect, or if they may be 
interchangeable.
The majority of published studies have used autolo-
gous platelet products albeit two studies using an allo-
geneic source have also reported successful outcomes.43 
Autologous products do not revoke an immune response; 
however their use may not represent an available option in 
every patient including those immuno-compromised 
patients, or patients with infectious disease.
Conclusion
There is an urgent need to reach international consensus on 
a standardized reporting system on platelet products. 
Researchers from other areas have proposed a PAW clas-
sification system encoding three key elements: the abso-
lute number of platelets, method of platelet activations and 
presence of white blood cells when referring a platelet 
product.12 Furthermore, based on the review, our recom-
mendation would be to incorporate the following key 
criteria into method preparation to ensure a more effective 
comparison across multiple studies, that is; the presence of 
leukocytes; platelet activation taking into consideration 
storage condition (freeze/thaw cycle); growth factor mea-
surement to at least include PDGF and EGF; and cytokine 
profiling, in particular when autologous platelet product is 
used. Along with the standardizing and accurate reporting 
of the actual platelet product formulation, other research-
ers have also stressed the importance of standardizing 
treatment regimen to reflect information such as dose- 
size modulation, mode of delivery to ocular surface, length 
of treatment and number of cycles.57
Research and clinical studies have shown that platelet- 
derived products are likely to provide a superior healing 
effect in the treatment of ocular surface diseases in com-
parison to standard, currently available treatments. This 
suggests an ongoing, if not increasing role for platelets 
and derived products in clinical treatments. It is important 
at this stage to recognize the great potential of using 
platelet products but also its associated challenges, limita-
tions, and potential risks to prepare a better and safer 
product for wider use in clinics.
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